Over 38 million people worldwide are indicated as suffering from atrial fibrillation, but -- due to rare, dangerous rhythm side effects -- access to heart rhythm drugs is restricted by the required three-day hospitalization to start these oral medications. The objective of the Safebeat Rx Inc SBIR is to expand access to these life-saving medications, which are currently under-prescribed to minority and rural populations due to the required hospitalization. The proposed research will advance technology created by SafeBeat Rx to allow atrial fibrillation patients to start medications safely at home via automated mobile heart rhythm analysis.
